Abstract

Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4

Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson

Issue: Jul/Aug 2025 - Volume 29, Number 4

Page(s): 319-327

Download in electronic PDF format for $75
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 1
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 2
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 3
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 4
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 5
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 6
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 7
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 8
  • Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4 Page 9

Abstract

Many psychiatric and neurological medications lack commercial liquid formulations, requiring extemporaneous compounding for patients unable to swallow solid dosage forms. While chemical stability data support extended beyond-use dating for various APIs in SyrSpend® SF PH4, antimicrobial effectiveness data essential for USP <795> compliance remain limited. To evaluate antimicrobial effectiveness and physicochemical stability of seven commonly compounded psychiatric and neurological drug suspensions in SyrSpend® SF PH4 to support evidence-based beyond-use dating decisions. Suspensions of amitriptyline hydrochloride (10.0 mg/mL), clonazepam (0.2 mg/mL), haloperidol (0.5 mg/mL), lorazepam (1.0 mg/mL), naltrexone hydrochloride (1.0 mg/mL), pregabalin (20.0 mg/mL), and sertraline hydrochloride (10.0 mg/mL) were prepared and stored at ambient and refrigerated conditions. USP <51> antimicrobial effectiveness testing was conducted alongside pH and visual appearance assessments. All formulations achieved USP <51> bacterial reduction criteria for E. coli, P. aeruginosa, and S. aureus. Complete C. albicans control was demonstrated in all formulations. A. brasiliensis showed variable responses, with persistent counts in naltrexone, pregabalin, and sertraline formulations, though remaining within USP acceptance limits. pH stability was maintained (3.3 - 5.1) with no visual changes observed. Storage temperature did not significantly affect stability. Results support beyond-use dating recommendations for all APIs at all conditions. These evidence-based recommendations provide compounding pharmacists with USP-compliant guidance for safe extended beyond-use dating while maintaining appropriate safety margins for pediatric, geriatric, and other vulnerable populations.

Related Keywords

  • Psychiatric drugs
  • Neurological drugs
  • SyrSpend SF PH4
  • Antimicrobial effectiveness testing
  • USP <51>
  • Physicochemical stability
  • Beyond-use dating
  • Oral suspensions
  • Extemporaneous compounding
  • pH stability

Related Categories

  • EXCIPIENTS
  • MENTAL HEALTH
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2025
Pg. 319-327
Antimicrobial Effectiveness and Physicochemical Stability of Compounded Psychiatric and Neurological Drug Suspensions in SyrSpend® SF PH4
Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson
Jul/Aug 2025
Pg. 310-318
Antimicrobial Stability, pH, and Physical Appearance of Cardiovascular Drug Suspensions in SyrSpend® SF PH4: A Complementary Evaluation
Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson
Mar/Apr 2014
Pg. 123-130
Quality Control Analytical Methods: The Essentials of United States Pharmacopeia Chapter <51> Antimicrobial Effectiveness Testing and Its Application in Pharmaceutical Compounding
Author(s): Vu Nicole, Nguyen Devin, Kupiec Thomas C
May/Jun 2025
Pg. 222-238
Physicochemical and Microbiological Stability of Commonly Prescribed APIs in SyrSpend® SF PH4: A Comprehensive Compatibility Study
Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson
Sep/Oct 2025
Pg. 409-419
Microbiological and Physical Stability of Extemporaneous Oral Suspensions Compounded with SyrSpend® SF PH4
Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Mar/Apr 2021
Pg. 169-175
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt
Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
Mar/Apr 2020
Pg. 134
Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 420-427
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 53
Ketoprofen 20-mg/mL in SyrSPend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2013
Pg. 344-346
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
Nov/Dec 2017
Pg. 491
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 412
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 140
Alprazolam 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 133
Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Jan/Feb 2021
Pg. 46
Diclofenac Sodium 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2021
Pg. 115-124
Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice
Author(s): Kelley Brian